← board
CTXR
distress 10/10 · high distress / dilution risk$0.53-5%today-71% from 52w high
Lead: recurrent or refractory gynecologic malignancies
Revenue
pre-revenue
Liquidity
$5M
Runway
0.2 yrs
Shares 1y
+61%
Price & events
-37.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.8%
1D
+4.7%
1W
-4.5%
1M
-42.7%
3M
-37.1%
6M
-67.6%
1Y
-97.7%
2Y
-98.9%
5Y
-97.9%
All
Overview
- Market Cap
- $14.68M
- Volume
- 28.64K
- 52 Week Range
- $0.48 – $1.82
- Total Shares
- 27.45M
- Float Shares
- 26.96M
- Short %
- 17.67%
- % Held by Insiders
- 1.80%
- % Held by Institutions
- 3.63%
- RVOL
- 0.10x
- Beta
- 0.98
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- May 30, 2026 at ASCO Annual Meetingconferencedata presentationsecondaryPhase 1LYMPHIR · Phase 1 data presented at ASCO for LYMPHIR + pembrolizumab combinationSEC 8-K
- 2026-04-29partnershipLYMPHIR (denileukin diftitox-cxdl) · Initial shipment of LYMPHIR to Europe through a regional distribution partner.SEC 8-K
- March 4, 2026readoutPhase 1LYMPHIR · Positive topline safety and efficacy results from Phase 1 trial evaluating LYMPHIR prior to commercial CAR-T therapy.SEC 8-K
- 2025-10-01partnershipLYMPHIR · Exclusive distribution agreement with Integris Pharma for 12 marketsSEC 8-K
- 2024-11-25fda agreementMino-Lok · Productive Type C meeting; FDA provided guidance supporting NDA submissionSEC 8-K
- 2024-08-12partnershipCompleted merger of Citius Oncology subsidiary with TenX Keane Acquisition; Citius Pharma retains 92.6% ownership.SEC 8-K
Approved drugs (2)
- LYMPHIRDENILEUKIN DIFTITOX-CXDL2024 · Prescription
- SUPRENZAPHENTERMINE HYDROCHLORIDE2012 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-11D. Boral CapitalBuy
- 2025-12-04D. Boral CapitalBuy
- 2025-08-13D. Boral CapitalBuy
- 2025-06-30D. Boral CapitalBuy
- 2025-06-10D. Boral CapitalBuy
- 2025-06-09D. Boral CapitalBuy
Competitors — recurrent or refractory gynecologic malignancies
- none identified
Recent news
- 2026-07-22Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
- 2026-07-21Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar
- 2026-07-21Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Yahoo Finance
- 2026-07-15Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
- 2026-07-14Citius Pharmaceuticals (CTXR) Edges Lower, Testing Key Support at $0.51 - IV Crush Alert - dars.gov.et
- 2026-06-25CTXR Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-01Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
- 2026-05-28Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.